The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Terrana is aiming to have commercially available products in the next few years, pending regulatory approval, that can be applied as sprayables or seed treatments. And the company says its RNA-based ...

Some of the market’s most expensive stocks are also its weakest earners, bleeding losses despite lofty valuations. For ...

CLEBURNE, Texas — The ACU Wildcats are set to participate in the 2026 College Baseball Series in Cleburne. The four-team ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...